OSTEOPORE LIMITED — M&A Activity 2022

Jul 31, 2022

==> picture [596 x 87] intentionally omitted <==

Singular Health Group Ltd: SHG

ASX Announcement

1 August 2022

Osteopore Ltd (ASX: OSX) to commercially launch 3Dicom VSP module and jointly assess M&A opportunities with signing of Collaboration Agreement

• Osteopore has agreed to four multi-year licenses of the 3Dicom R&D software and 3Dicom VSP module as the first enterprise partner to offer 3Dicom VSP to their users.

• Enterprise licenses to be jointly branded within 3Dicom VSP and User Portal and Osteopore will actively promote the 3Dicom software to their extensive list of surgeons.

• Singular Health and Osteopore have also agreed to jointly assess potential merger and acquisition (M&A) opportunities and collaborate on various business activities including marketing and sales in the USA and Australia.

• Singular Health and Osteopore remain committed to conducting previously announced comparative study, with Osteopore paying for further modifications to AI cranial model.

1 August 2022 – Medical technology company Singular Health Group Ltd (ASX: SHG) (“Singular Health”, or “the Company”) is pleased to announce a closer working relationship with Osteopore Ltd (ASX: OSX) through the signing of a collaboration agreement to procure four enterprise licenses for 3Dicom, promote the Company’s software, jointly assess M&A opportunities, and collaborate on business activities in the USA and Australia.

==> picture [392 x 216] intentionally omitted <==

Figure 1: The 3Dicom VSP software allows Osteopore to share virtual models of the cranium and cranial implants with end-users for training, educational and visualisation purposes anytime and anywhere.

==> picture [596 x 88] intentionally omitted <==

==> picture [137 x 43] intentionally omitted <==

Enterprise Licenses of 3Dicom R&D and 3Dicom VSP

Following evaluation of the recently completed 3Dicom VSP module for Virtual Reality, whereby Osteopore and Singular staff remotely collaborated on cranial scans in real-time, Osteopore has agreed to four enterprise licenses of the 3Dicom R&D software and VSP module. These four licenses will see Osteopore branding added to the 3Dicom User Portal for Osteopore’s surgeons and the ability for Osteopore’s surgeons to visualise the OSX products in Virtual Reality along with their own scans for training and marketing purposes.

Comparative Study and Development of Skirted AI Cranial Implant Model

As per the ASX Announcement (“SHG & CSIRO AI Tool to Optimise Cranial Implant Procedures”) dated 14[th] March 2022, Singular and Osteopore continue to work on modifying the AI-based cranial implant model to suit the Osteopore manufacturing process with the addition of a ‘skirt’ and netting of the implant. This work continues to progress ahead of the planned comparative study in a clinical setting.

==> picture [389 x 211] intentionally omitted <==

Figure 2: Osteopore's US Sales Manager, Kean Lee, and Singular Health’s COO, James Hill, at American Association of Neurological Surgeons’ (AANS) Annual Conference in Philadelphia in early-May 2022

Joint Assessment of Potential Corporate and Commercial Opportunities

Following separate representation at the American Association of Neurological Surgeon’s (AANS) Annual Conference in the USA and discussions with numerous medical implant designers and manufacturers by Osteopore and Singular individually, many opportunities have arisen both at an operational/commercial level and at a corporate level.

With Osteopore providing both a cutting-edge material and manufacturing technique, and Singular Health providing design software and an integrated means for surgeons and designers to collaborate in future, the synergies of combining design and manufacture have already led to joint presentations and conversations by Osteopore and Singular Health to third parties in the USA, Australia, and Europe.

With both Singular and Osteopore already having informally facilitated introductions to third parties, today’s collaboration agreement helps to formalise future collaborative activities as the Companies assess potential M&A opportunities in the USA, Australia, and Europe. These conversations steadily progress towards corporate and commercial outcomes.

==> picture [594 x 30] intentionally omitted <==

ASX: SHG | www.singular.health

2

==> picture [137 x 43] intentionally omitted <==

Announcing the collaboration agreement, Singular Health Managing Director, Thomas Hanly, said:

“This agreement builds on our existing research collaboration with Osteopore and the CSIRO to build an Artificial Intelligence Tool that can design a Patient Specific Cranial Implant from a CT scan using our 3Dicom Software Suite. From that initial collaboration, the two companies have been active in reviewing and developing commercial opportunities using our software and Osteopore’s bio-resorbable material in Australia, the USA, and South-East Asia.

The cranial AI tool built from our original agreement has now been complemented with a skirt or flange that confirms to the unique requirements of Osteopore’s bio-resorbable material and reduces the time taken to design a patient specific implant from up to 3 hours to less than 30 minutes with custom edits. This positions the two companies squarely in the global cranial implant market which according to the December 2021 Global Cranial Implants Market Analysis (2021-2027) from KBV Research is valued $1.679 Billion by 2027 with a combined annual growth rate of 11.5%.”

Following the agreement, Khoon Seng Goh, Osteopore’s CEO, commented:

“This is an exciting opportunity as it allows Osteopore to provide a more holistic solution to our partners and surgeons. We hope to provide our partners and surgeons with the better quality tools to help improve the quality of patient care.”

This announcement is authorised for release by the Board of Directors of the Company.

Ends

For further information contact

Investors	Corporate	Media
James Hill +61 413 825 646 jhill@singular.health	Steven Wood Company Secretary sw@grangeconsulting.com.au	Julia Maguire The Capital Network julia@thecapitalnetwork.com.au

About Singular Health:

Singular Health Group Limited (ASX:SHG) is a medical technology company that empowers practitioners and patients via personalised surgical planning solutions that drive better health outcomes.

Singular Health has developed a proprietary Volumetric Rendering Platform (VRP) that leverages existing 2D radiological images to generate fully immersive patient-specific 3D/VR models. Although Singular Health’s VRP technology is applicable to other sectors in which the visualisation of dynamic data is crucial, with it already being utilised in the mining sector, the Company’s core focus is on the medical sector.

Complementing its VRP technology, Singular Health has acquired Virtual Surgical Planning software and a 25% stake in medical-grade 3D printing company Additive Engineering.

==> picture [594 x 30] intentionally omitted <==

ASX: SHG | www.singular.health

3

==> picture [137 x 43] intentionally omitted <==

These investments represent key milestones in Singular Health’s efforts to commercialise its ‘Scan to Surgery’ initiative, a world-first vertically integrated platform that revolutionises the planning and execution of personalised surgical procedures.

A successful full-scale commercialisation of this end-to-end personalised surgical planning platform will give Singular Health the capability to penetrate a multi-billion-dollar global market opportunity in the medical visualisation and additive manufacturing spaces.

With Singular Health, practitioners are empowered by having the ability to collaborate with producers of patient-specific medical components in real-time while patients benefit from having access to easily comprehensible and enhanced medical information.

To learn more, please visit: www.singular.health

About Osteopore Limited:

Osteopore Ltd, an Australian ASX listed company (ASX: OSX) with R&D and manufacturing in Singapore, is the global leader in the manufacture of innovative regenerative implants at commercial scale. By combining biomimetic tissue science with proprietary 3D printing and materials technology, Osteopore produces medical implants to meet the needs of both tissue and bone reconstruction as well as restoration. These bioresorbable implants provide a scaffold for bone regeneration, dissolving predictably over time to leave only natural bone tissue. In collaboration with clinicians and researchers, Osteopore develops and manufactures implants that address unmet clinical needs which improve patient outcomes, enhances lives, and potentially reduces healthcare costs.

For more information, visit us at www.osteopore.com

==> picture [594 x 30] intentionally omitted <==

ASX: SHG | www.singular.health

4